Acomplia
From News about the diet drug Acomplia
What is Acomplia (Rimonabant), is it a weight loss pill?
Yes, Acomplia is a weight loss pill. Rimonabant acomplia is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Obesity is now the most common nutritional disorder in western countries. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the body from overconsumption of fatty foods. Prevalence of obesity in the US and Europe has reached epidemic levels. Data from the World Health Organisation's MONICA project show that in some parts of Europe over 70% of men aged 55-64 years are clinically obese or overweight (BMI >25) and almost 70% of women in this age group. One in five of all Americans is obese and one in three overweight. Furthermore, increasing rates of childhood obesity are likely to exacerbate the trend towards increasing obesity in adulthood. Kick Your obesity with Mircale diet pill, buy Acomplia Rimonabant Zimulti, your one stop weight loss medication. Acomplia is a French drug designed to quit the smoking and check obesity. It suppresses the appetite by blocking hunger signals to brain.Acomplia affects endocannabinoid system.Acomplia targets newly discovered hunger center Cannabinoid receptors in the brain thus controlling the hunger. It is a wonderful drug for treatment of obesity in a differentmanner. Acompliais known to reduces lower triglycerides, improved the HDL (good ) cholesterol levels as well as helped desensitize insulin levels in the blood. Acomplia would not lead to weight gain after quitting smoking.
How does Acomplia works, has it been tested on human subjects?
Since the launch of Acomplia, sanofi-aventis has worked closely to monitor safety, and in conjunction with clinicians and regulatory agencies has actively sought to ensure that treatment is prescribed to the right patient - those who need to reduce their weight as a health priority - whilst minimising use in the wrong patient, in particular excluding those who currently are or who have in the past been depressed. Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle. CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system). The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism. About two-thirds of Americans are overweight or obese, according to authors F Xavier Pi-Sunyer, MD, of the Obesity Research Center, St Luke's-Roosevelt Hospital, New York, and colleagues. Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle. Buy Acomplia not only if your weight problems, it will also helo you stop smoking. This excess weight greatly increases the risk of developing diabetes mellitus and heart disease and death from related causes. For this reason, researchers believe, obesity-management goals should include not only weight-loss (particularly around the waist), but also the improvement of cardio-metabolic risk factors, including abnormal cholesterol and blood sugar levels. CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism. Acomplia (rimonabant) has been available in Europe since the middle of 2006, following regulatory approval by the EMEA in June 2006 for its use as an adjunct to diet and exercise for obese or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaeamia, so you can buy acomplia (rimonabant), it is safe to use and already tested.
What were the results of Acomplia Clinical trial studies?
Results found that:
Acomplia patients lost 4.7kg more than the placebo patients after one year Acomplia patients ran a 40% higher risk of experiencing adverse events or serious adverse events, compared to the placebo patients. Acomplia patients ran 2.5 times the risk of discontinuing treatment because of depression, compared to the placebo patients. Acomplia patients ran 3.5 times the risk of discontinuing treatment due to anxiety, compared to the placebo patients. "As with other weight-loss drugs, relapse is expected to occur after treatment has ended, and to achieve weight maintenance and maintain the improvement of the cardiovascular and diabetes risk factors the drug needs to be taken for life," the researchers explained. "Our findings suggest that 20 mg per day of rimonabant increases the risk of psychiatric events - i.e., depressed mood disorders and anxiety - despite depressed mood being an exclusion criterion in these trials. Taken together with the recent US Food and Drug Administration finding of increased risk of suicide during treatment with rimonabant, we recommend increased alertness by physicians to these potentially severe psychiatric adverse reactions," the authors concluded. Acomplia has been authorised in the EU since June 2006 as an adjunct to diet and exercise for the treatment of obese or overweight adult patients. Psychiatric side effects, in particular depression, were identified as the main safety issue at the time of approval. They were reflected in the medicine's product information as a warning that doctors should not prescribe Acomplia in patients with uncontrolled serious psychiatric conditions such as major depression. In clinical studies, Acomplia has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss. Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Acomplia 20mg was beyond that expected from weight loss.
